CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies

Authors

  • Xinni Luo,

    1. Department of Neurology, Guangzhou Brain Hospital, Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong, China
    Search for more papers by this author
  • Le Hou,

    1. Department of Neurology, Guangzhou Brain Hospital, Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong, China
    Search for more papers by this author
  • Haishan Shi,

    1. Department of Neurology, Guangzhou Brain Hospital, Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong, China
    Search for more papers by this author
  • Xiaomei Zhong,

    1. Department of Neurology, Guangzhou Brain Hospital, Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong, China
    Search for more papers by this author
  • Yufeng Zhang,

    1. Department of Neurology, Guangzhou Brain Hospital, Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong, China
    Search for more papers by this author
  • Dong Zheng,

    1. Department of Neurology, Guangzhou Brain Hospital, Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong, China
    Search for more papers by this author
  • Yan Tan,

    1. Department of Neurology, Guangzhou Brain Hospital, Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong, China
    Search for more papers by this author
  • Guoyan Hu,

    1. Medical Laboratory, Guangzhou Brain Hospital, Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong, China
    Search for more papers by this author
  • Nan Mu,

    1. Department of Geriatrics, Guangzhou Brain Hospital, Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong, China
    Search for more papers by this author
  • Jianping Chan,

    1. Department of Geriatrics, Guangzhou Brain Hospital, Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong, China
    Search for more papers by this author
  • Xinru Chen,

    1. Department of Neurology, Guangzhou Brain Hospital, Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong, China
    Search for more papers by this author
  • Yaxiu Fang,

    1. Department of Neurology, Guangzhou Brain Hospital, Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong, China
    Search for more papers by this author
  • Fengchun Wu,

    1. Department of Schizophrenia, Guangzhou Brain Hospital, Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong, China
    Search for more papers by this author
  • Hongbo He,

    1. Neuropsychiatry Research Institute, Guangzhou Brain Hospital, Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong, China
    Search for more papers by this author
  • Yuping Ning

    Corresponding author
    1. Department of Neurology, Guangzhou Brain Hospital, Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong, China
    • Address correspondence and reprint requests to Yuping Ning, Guangzhou Brain Hospital, Affiliated Hospital of Guangzhou Medical College, Department of Neurology, No. 36 Mingxin Road, Liwan district, 510370 Guangzhou, Guangdong, China. E-mail: ningjeny@126.com

    Search for more papers by this author

Abstract

The overlapping clinical features of Alzheimer's disease (AD) and Dementia with Lewy bodies (DLB) make differentiation difficult in the clinical environment. Evaluating the CSF levels of biomarkers in AD and DLB patients could facilitate clinical diagnosis. CSF Visinin-like protein-1 (VILIP-1), a calcium-mediated neuronal injury biomarker, has been described as a novel biomarker for AD. The aim of this study was to investigate the diagnostic utility of CSF VILIP-1 and VILIP-1/Aβ1–42 ratio to distinguish AD from DLB. Levels of CSF VILIP-1, t-tau, p-tau181P, Aβ1–42, and α-synuclein were measured in 61 AD patients, 32 DLB patients, and 40 normal controls using commercial ELISA kits. The results showed that the CSF VILIP-1 level had significantly increased in AD patients compared with both normal controls and DLB patients. The CSF VILIP-1 and VILIP-1/Aβ1–42 levels had enough diagnostic accuracy to allow the detection and differential diagnosis of AD. Additionally, CSF VILIP-1 levels were positively correlated with t-tau and p-tau181P within each group and with α-synuclein in the AD and control groups. We conclude that CSF VILIP-1 could be a diagnostic marker for AD, differentiating it from DLB. The analysis of biomarkers, representing different neuropathologies, is an important approach reflecting the heterogeneous features of AD and DLB.

image

Neuronal Ca2+-sensor protein VILIP-1 has been implicated in the calcium-mediated neuronal injury and pathological change of AD. The CSF VILIP-1 and VILIP-1/Aβ1-42 levels had enough diagnostic accuracy to allow the detection and differential diagnosis of AD. CSF VILIP-1 is a useful biomarker for AD. Evaluating the CSF levels of VILIP-1 in AD and DLB patients could facilitate clinical diagnosis.

Ancillary